Publisher： Bentham Science Publishers
E-ISSN： 1873-5576|3|5|325-330
ISSN： 1568-0096
Source： Current Cancer Drug Targets, Vol.3, Iss.5, 2003-10, pp. : 325-330
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The currently used Hsp90 inhibitors, geldanamycin, herbimycin A and radicicol, were isolated many years ago from Streptomyces and fungi originally for their antiprotozoal activity, herbicidal activity and antifungal activity, respectively. In the mid 1980s, it was found that the benzoquinone ansamycin antibiotics (herbimycin A, geldanamycin, and macbecin) reversed v-Src transformed cells to normal phenotypes, and Bcr-abl was subsequently suggested to be the molecular target for the treatment of chronic myelogenous leukemia through a study using herbimycin A for its selective antioncogenic activity. In 1994, these ansamycins were found to bind to Hsp90 and to cause the degradation of client proteins including Src kinases; further efforts to develop anticancer drugs were made using geldanamycin analogs, and 17AAG was chosen as the best candidate for clinical trials. The number of novel natural products isolated from microbial origins is continuing to increase and is doubling every 10 years. Thus, screening of bioactive substances from natural origins, using assays including defined targets, and developing leads toward drugs via optimized derivatization is a conventional but still promising strategy for drug discovery and development.
Related content
Access to resources
Recommend
Macrocyclic Inhibitors of Hsp90
Current Topics in Medicinal Chemistry, Vol. 10, Iss. 14, 2010-10 ,pp. :
Medicinal Chemistry of Hsp90 Inhibitors
Current Topics in Medicinal Chemistry, Vol. 8, Iss. 10, 2008-07 ,pp. :
Purine-Scaffold Hsp90 Inhibitors
Current Topics in Medicinal Chemistry, Vol. 9, Iss. 15, 2009-11 ,pp. :